Chromocell Therapeutics (Chromocell Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics ROE % Adjusted to Book Value?

Chromocell Therapeutics's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Chromocell Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was 13.37. Chromocell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 0.00%.

Chromocell Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Chromocell Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics ROE % Adjusted to Book Value Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Chromocell Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Chromocell Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chromocell Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's ROE % Adjusted to Book Value falls into.

Chromocell Therapeutics ROE % Adjusted to Book Value Calculation

Chromocell Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

Chromocell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	13.37
	=	0.00%

Chromocell Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.